244 related articles for article (PubMed ID: 24567278)
1. Long-term efficacy of OROS® hydromorphone combined with pregabalin for chronic non-cancer neuropathic pain.
Dauri M; Lazzari M; Casali M; Tufaro G; Sabato E; Sabato AF
Clin Drug Investig; 2014 May; 34(5):309-16. PubMed ID: 24567278
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
Hale M; Tudor IC; Khanna S; Thipphawong J
Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906
[TBL] [Abstract][Full Text] [Related]
3. Open-label study to evaluate the efficacy and safety of extended-release hydromorphone in patients with chronic neuropathic pain.
Nalamachu S; Ruck D; Nalamasu R; Fasbinder S; Bansal R
J Opioid Manag; 2013; 9(1):43-9. PubMed ID: 23709303
[TBL] [Abstract][Full Text] [Related]
4. A prospective multicentre study to evaluate the efficacy and tolerability of osmotic release oral system (OROS) hydromorphone in opioid-naive cancer patients: Results of the Korean South West Oncology Group study.
Song EK; Shim H; Han HS; Sun D; Lee SI; Kang MH; Lee K; Cho D; Cho IS; Park SY; Kim S; Yim CY
Pain Res Manag; 2015; 20(6):293-9. PubMed ID: 26474382
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of pregabalin using a flexible, optimized dose schedule in Korean patients with peripheral neuropathic pain: a 10-week, randomized, double-blind, placebo-controlled, multicenter study.
Moon DE; Lee DI; Lee SC; Song SO; Yoon DM; Yoon MH; Kim HK; Lee YW; Kim C; Lee PB
Clin Ther; 2010 Dec; 32(14):2370-85. PubMed ID: 21353106
[TBL] [Abstract][Full Text] [Related]
6. Safety and Tolerability of Once-Daily OROS(®) hydromorphone extended-release in opioid-tolerant adults with moderate-to-severe chronic cancer and noncancer pain: pooled analysis of 11 clinical studies.
Nalamachu SR; Kutch M; Hale ME
J Pain Symptom Manage; 2012 Dec; 44(6):852-65. PubMed ID: 22795050
[TBL] [Abstract][Full Text] [Related]
7. Hydromorphone extended release for neuropathic and non-neuropathic/nociceptive chronic low back pain: a post hoc analysis of data from a randomized, multicenter, double-blind, placebo-controlled clinical trial.
Nalamachu S; Hale M; Khan A
J Opioid Manag; 2014; 10(5):311-22. PubMed ID: 25350473
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of the sustained-release hydromorphone in neuropathic pain management: pooled analysis of three open-label studies.
Moulin DE; Richarz U; Wallace M; Jacobs A; Thipphawong J
J Pain Palliat Care Pharmacother; 2010 Sep; 24(3):200-12. PubMed ID: 20718640
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of pregabalin for peripheral neuropathic pain: results of an 8-week, flexible-dose, double-blind, placebo-controlled study conducted in China.
Guan Y; Ding X; Cheng Y; Fan D; Tan L; Wang Y; Zhao Z; Hong Z; Zhou D; Pan X; Chen S; Martin A; Tang H; Cui L
Clin Ther; 2011 Feb; 33(2):159-66. PubMed ID: 21444113
[TBL] [Abstract][Full Text] [Related]
10. Sustained safety and efficacy of once-daily hydromorphone extended-release (OROS® hydromorphone ER) compared with twice-daily oxycodone controlled-release over 52 weeks in patients with moderate to severe chronic noncancer pain.
Richarz U; Waechter S; Sabatowski R; Szczepanski L; Binsfeld H
Pain Pract; 2013 Jan; 13(1):30-40. PubMed ID: 22510252
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of OROS® hydromorphone ER in adults with chronic noncancer and cancer pain: pooled analysis of 13 studies.
Hale ME; Wallace MS; Taylor DR; Kutch M; Nalamachu S
J Opioid Manag; 2012; 8(5):299-314. PubMed ID: 23247907
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies.
Semel D; Murphy TK; Zlateva G; Cheung R; Emir B
BMC Fam Pract; 2010 Nov; 11():85. PubMed ID: 21054853
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety, tolerability, and efficacy of OROS hydromorphone in patients with chronic pain.
Wallace M; Moulin DE; Rauck RL; Khanna S; Tudor IC; Skowronski R; Thipphawong J
J Opioid Manag; 2009; 5(2):97-105. PubMed ID: 19507806
[TBL] [Abstract][Full Text] [Related]
14. Impact of pregabalin treatment on pain, pain-related sleep interference and general well-being in patients with neuropathic pain: a non-interventional, multicentre, post-marketing study.
Anastassiou E; Iatrou CA; Vlaikidis N; Vafiadou M; Stamatiou G; Plesia E; Lyras L; Vadalouca A;
Clin Drug Investig; 2011; 31(6):417-26. PubMed ID: 21466244
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety evaluation of once-daily OROS hydromorphone in patients with chronic low back pain: a pilot open-label study (DO-127).
Wallace M; Skowronski R; Khanna S; Tudor IC; Thipphawong J
Curr Med Res Opin; 2007 May; 23(5):981-9. PubMed ID: 17519065
[TBL] [Abstract][Full Text] [Related]
16. Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain.
Hale M; Khan A; Kutch M; Li S
Curr Med Res Opin; 2010 Jun; 26(6):1505-18. PubMed ID: 20429852
[TBL] [Abstract][Full Text] [Related]
17. A prospective, open-label, multicentre study of pregabalin in the treatment of neuropathic pain in Latin America.
Xochilcal-Morales M; Castro EM; Guajardo-Rosas J; Obregón TN; Acevedo JC; Chucan JM; Plancarte-Sanchez R; Davila G; Wajsbrot D; Guerrero M; Vinueza R
Int J Clin Pract; 2010 Aug; 64(9):1301-9. PubMed ID: 20487048
[TBL] [Abstract][Full Text] [Related]
18. Antiepileptic drugs for chronic non-cancer pain in children and adolescents.
Cooper TE; Wiffen PJ; Heathcote LC; Clinch J; Howard R; Krane E; Lord SM; Sethna N; Schechter N; Wood C
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD012536. PubMed ID: 28779491
[TBL] [Abstract][Full Text] [Related]
19. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study.
Tölle T; Freynhagen R; Versavel M; Trostmann U; Young JP
Eur J Pain; 2008 Feb; 12(2):203-13. PubMed ID: 17631400
[TBL] [Abstract][Full Text] [Related]
20. An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS(R) hydromorphone in patients with chronic cancer pain.
Hanna M; Tuca A; Thipphawong J
BMC Palliat Care; 2009 Sep; 8():14. PubMed ID: 19754935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
